Literature DB >> 28366935

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

D Jones1, J A Woyach2, W Zhao1, S Caruthers3, H Tu3, J Coleman1, J C Byrd2, A J Johnson2, G Lozanski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28366935     DOI： 10.1038/leu.2017.110

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  BLNK: connecting Syk and Btk to calcium signals.

Authors:  T Kurosaki; S Tsukada
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

2.  Electrostatic control of the membrane targeting of C2 domains.

Authors:  Diana Murray; Barry Honig
Journal:  Mol Cell       Date:  2002-01       Impact factor: 17.970

Review 3.  Dysfunction of phospholipase Cγ in immune disorders and cancer.

Authors:  Hans Koss; Tom D Bunney; Sam Behjati; Matilda Katan
Journal:  Trends Biochem Sci       Date:  2014-10-30       Impact factor: 13.807

4.  Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Authors:  Kah-Lok Chan; Piers Blombery; Kate Jones; Stephen Lade; Dennis Carney; Huy Tran; John F Seymour; Constantine S Tam
Journal:  Br J Haematol       Date:  2016-05-15       Impact factor: 6.998

5.  Ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Richard R Furman; Shuhua Cheng; Pin Lu; Menu Setty; Alexendar R Perez; Alijandro R Perez; Ailin Guo; Joelle Racchumi; Guozhou Xu; Hao Wu; Jiao Ma; Susanne M Steggerda; Morton Coleman; Christina Leslie; Y Lynn Wang
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

6.  Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Authors:  Adam R Johnson; Pawan Bir Kohli; Arna Katewa; Emily Gogol; Lisa D Belmont; Regina Choy; Elicia Penuel; Luciana Burton; Charles Eigenbrot; Christine Yu; Daniel F Ortwine; Krista Bowman; Yvonne Franke; Christine Tam; Alberto Estevez; Kyle Mortara; Jiansheng Wu; Hong Li; May Lin; Philippe Bergeron; James J Crawford; Wendy B Young
Journal:  ACS Chem Biol       Date:  2016-09-07       Impact factor: 5.100

7.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Authors:  Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel
Journal:  Nat Immunol       Date:  2013-10-28       Impact factor: 25.606

8.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; Amy S Ruppert; Daphne Guinn; Amy Lehman; James S Blachly; Arletta Lozanski; Nyla A Heerema; Weiqiang Zhao; Joshua Coleman; Daniel Jones; Lynne Abruzzo; Amber Gordon; Rose Mantel; Lisa L Smith; Samantha McWhorter; Melanie Davis; Tzyy-Jye Doong; Fan Ny; Margaret Lucas; Weihong Chase; Jeffrey A Jones; Joseph M Flynn; Kami Maddocks; Kerry Rogers; Samantha Jaglowski; Leslie A Andritsos; Farrukh T Awan; Kristie A Blum; Michael R Grever; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 50.717

9.  Structural and functional integration of the PLCγ interaction domains critical for regulatory mechanisms and signaling deregulation.

Authors:  Tom D Bunney; Diego Esposito; Corine Mas-Droux; Ekatarina Lamber; Rhona W Baxendale; Marta Martins; Ambrose Cole; Dmitri Svergun; Paul C Driscoll; Matilda Katan
Journal:  Structure       Date:  2012-10-11       Impact factor: 5.006

10.  Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Authors:  Jan A Burger; Dan A Landau; Amaro Taylor-Weiner; Ivana Bozic; Huidan Zhang; Kristopher Sarosiek; Lili Wang; Chip Stewart; Jean Fan; Julia Hoellenriegel; Mariela Sivina; Adrian M Dubuc; Cameron Fraser; Yulong Han; Shuqiang Li; Kenneth J Livak; Lihua Zou; Youzhong Wan; Sergej Konoplev; Carrie Sougnez; Jennifer R Brown; Lynne V Abruzzo; Scott L Carter; Michael J Keating; Matthew S Davids; William G Wierda; Kristian Cibulskis; Thorsten Zenz; Lillian Werner; Paola Dal Cin; Peter Kharchencko; Donna Neuberg; Hagop Kantarjian; Eric Lander; Stacey Gabriel; Susan O'Brien; Anthony Letai; David A Weitz; Martin A Nowak; Gad Getz; Catherine J Wu
Journal:  Nat Commun       Date:  2016-05-20       Impact factor: 14.919
View more
  19 in total

1.  LC-FACSeq is a method for detecting rare clones in leukemia.

Authors:  Eileen Y Hu; James S Blachly; Caner Saygin; Hatice G Ozer; Stephanie E Workman; Arletta Lozanski; Tzyy-Jye Doong; Chi-Ling Chiang; Seema Bhat; Kerry A Rogers; Jennifer A Woyach; Kevin R Coombes; Daniel Jones; Natarajan Muthusamy; Gerard Lozanski; John C Byrd
Journal:  JCI Insight       Date:  2020-06-18

2.  The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Authors:  Sean D Reiff; Rose Mantel; Lisa L Smith; J T Greene; Elizabeth M Muhowski; Catherine A Fabian; Virginia M Goettl; Minh Tran; Bonnie K Harrington; Kerry A Rogers; Farrukh T Awan; Kami Maddocks; Leslie Andritsos; Amy M Lehman; Deepa Sampath; Rosa Lapalombella; Sudharshan Eathiraj; Giovanni Abbadessa; Brian Schwartz; Amy J Johnson; John C Byrd; Jennifer A Woyach
Journal:  Cancer Discov       Date:  2018-08-09       Impact factor: 39.397

3.  Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.

Authors:  Elodie Pramil; Linda Herbi Bastian; Thomas Denèfle; Fariba Nemati; Malina Xiao; Eva Lardé; Karim Maloum; Damien Roos-Weil; Elise Chapiro; Magali Le Garff-Tavernier; Frédéric Davi; Didier Decaudin; Marika Sarfati; Florence Nguyen-Khac; Hélène Merle-Béral; Philippe Karoyan; Santos A Susin
Journal:  Blood Adv       Date:  2019-10-22

4.  Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.

Authors:  Arthur L Shaffer; James D Phelan; James Q Wang; DaWei Huang; George W Wright; Monica Kasbekar; Jaewoo Choi; Ryan M Young; Daniel E Webster; Yandan Yang; Hong Zhao; Xin Yu; Weihong Xu; Sandrine Roulland; Michele Ceribelli; Xiaohu Zhang; Kelli M Wilson; Lu Chen; Crystal McKnight; Carleen Klumpp-Thomas; Craig J Thomas; Björn Häupl; Thomas Oellerich; Zachary Rae; Michael C Kelly; Inhye E Ahn; Clare Sun; Erika M Gaglione; Wyndham H Wilson; Adrian Wiestner; Louis M Staudt
Journal:  Blood Cancer Discov       Date:  2021-09-14

5.  Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Lesley-Ann Sutton
Journal:  Hemasphere       Date:  2019-06-30

Review 6.  The potential of pirtobrutinib in multiple B-cell malignancies.

Authors:  Jeffrey L Jensen; Anthony R Mato; Camila Pena; Lindsey E Roeker; Catherine C Coombs
Journal:  Ther Adv Hematol       Date:  2022-06-16

7.  Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.

Authors:  Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

Review 8.  Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Rev Hematol       Date:  2018-02-12       Impact factor: 2.929

9.  Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells.

Authors:  Hui Jing; Alex Reed; Olesya A Ulanovskaya; Jan-Sebastian Grigoleit; Dylan M Herbst; Cassandra L Henry; Haoxin Li; Sabrina Barbas; Jason Germain; Kim Masuda; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

10.  Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder.

Authors:  Claudia Walliser; Martin Wist; Elisabeth Hermkes; Yuan Zhou; Anja Schade; Jennifer Haas; Julia Deinzer; Laurent Désiré; Shawn S C Li; Stephan Stilgenbauer; Joshua D Milner; Peter Gierschik
Journal:  Oncotarget       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.